logo

For the Inventor, By the Inventor

Marseille, France

Kamel Mabrouk

This inventor holds 5 USPTO granted patents. Top assignees: Cellpep Pharma Inc., Ambrilia Biopharma, Inc., Armel S.a.. Active years: 1997-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kamel Mabrouk. Retrieved from https://idiyas.com/inventor/kamel-mabrouk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 40.0

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Marseille, FR (1997)
  • Les Pennes-Mirabeau, FR (2007)
  • Les Pennes-Mirabeau, TN (2008)
  • Marseilles, FR (2002 - 2010)

Company Filing History:

goldMedal2 out of 3 
 
Cellpep Pharma Inc.
 patents
silverMedal1 out of 6 
 
Ambrilia Biopharma, Inc.
 patents
bronzeMedal1 out of 1 
 
Armel S.a.
 patent
4. 1 out of 1 
 
Gellpep S.a.
 patent

Years Active: 1997-2010

Loading Chart...
5 patents (USPTO):Explore Patents
1. 7829666 - Maurotoxin, PI1 and HSTX1 derivatives (2010-11-09),
2. 7319089 - Maurocalcine, analogues thereof and their therapeutical uses (2008-01-15),
3. 7285621 - Multiple branch peptide construction (2007-10-23),
4. 6379679 - Multiple branch peptide construction (2002-04-30),
5. 5622933 - Multiple branch peptide constructions for use against HIV (1997-04-22),

Title: Kamel Mabrouk: Innovator in Toxin Research

Introduction

Kamel Mabrouk is a prominent inventor based in Marseilles, France. He has made significant contributions to the field of toxin research, particularly in the development of novel derivatives that have therapeutic potential. With a total of 5 patents, his work focuses on addressing pathologies associated with calcium channel dysfunction.

Latest Patents

Mabrouk's latest patents include Maurotoxin, PI1, and HSTX1 derivatives. These derivatives of Maurotoxin (MTX) feature a disrupted native disulfide bridge pattern, which enhances their utility in treating conditions related to the dysfunction and activation of Ca-activated and voltage-gated K-channel subtypes, such as IKCa1 or Kv1.2. Notably, some derivatives involve substitutions of amino acid residues, resulting in a modified disulfide bridge pattern. Additionally, Maurocalcine and its analogues have been identified for their potential therapeutic uses, particularly in modifying the gating behavior of type 1 ryanodine receptors and as candidate immuno-suppressive drugs.

Career Highlights

Throughout his career, Kamel Mabrouk has worked with various companies, including Cellpep Pharma Inc. and Armel S.A. His innovative research has positioned him as a key figure in the field of toxin-based therapeutics.

Collaborations

Mabrouk has collaborated with notable professionals in his field, including Herve Rochat and Jean-Marc Sabatier. These collaborations have further enriched his research and development efforts.

Conclusion

Kamel Mabrouk's contributions to toxin research and his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for new therapeutic approaches to calcium channel-related pathologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…